Leerink Partnrs Weighs in on Replimune Group FY2025 Earnings

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities researchers at Leerink Partnrs cut their FY2025 EPS estimates for Replimune Group in a research note issued to investors on Wednesday, February 12th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($2.93) per share for the year, down from their prior forecast of ($2.82). The consensus estimate for Replimune Group's current full-year earnings is ($2.97) per share. Leerink Partnrs also issued estimates for Replimune Group's Q4 2025 earnings at ($0.69) EPS and FY2026 earnings at ($2.22) EPS.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09).

REPL has been the topic of several other research reports. BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $19.29.

Replimune Group Price Performance

NASDAQ REPL traded up $0.53 during trading on Monday, reaching $14.31. 1,031,331 shares of the company traded hands, compared to its average volume of 750,465. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -4.66 and a beta of 1.30. The stock's 50 day moving average price is $12.61 and its two-hundred day moving average price is $11.81. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in shares of Replimune Group during the third quarter worth $251,000. Creative Planning increased its stake in shares of Replimune Group by 28.7% during the 3rd quarter. Creative Planning now owns 21,047 shares of the company's stock worth $231,000 after purchasing an additional 4,699 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock valued at $144,000 after buying an additional 5,926 shares during the period. GSA Capital Partners LLP bought a new stake in Replimune Group in the 3rd quarter valued at $222,000. Finally, LMR Partners LLP lifted its holdings in Replimune Group by 145.8% during the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company's stock valued at $904,000 after purchasing an additional 48,920 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.